Your browser doesn't support javascript.
loading
BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.
Couraud, Sébastien; Souquet, Pierre-Jean; Paris, Christophe; Dô, Pascal; Doubre, Hélène; Pichon, Eric; Dixmier, Adrien; Monnet, Isabelle; Etienne-Mastroianni, Bénédicte; Vincent, Michel; Trédaniel, Jean; Perrichon, Marielle; Foucher, Pascal; Coudert, Bruno; Moro-Sibilot, Denis; Dansin, Eric; Labonne, Stéphanie; Missy, Pascale; Morin, Franck; Blanché, Hélène; Zalcman, Gérard.
Affiliation
  • Couraud S; Dept of Respiratory Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France Faculty of Medicine Lyon-Sud Charles Mérieux, Lyon 1 University, Lyon, France Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada Dept of
  • Souquet PJ; Dept of Respiratory Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France Faculty of Medicine Lyon-Sud Charles Mérieux, Lyon 1 University, Lyon, France.
  • Paris C; (CP) INGRES, EA7298, Lorraine University, Vandoeuvre Les Nancy, France.
  • Dô P; Francois Baclesse Cancer Institute, Caen, France.
  • Doubre H; Pulmonology Unit, Foch General Hospital, Paris, France.
  • Pichon E; Pulmonology Unit, University Hospital of Tours, Tours, France François Rabelais University, Respiratory Diseases Study Centre, U1100/EA6305, Tours, France.
  • Dixmier A; Pulmonology Unit, Orleans Regional Hospital, Orléans, France.
  • Monnet I; Pulmonology Unit, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
  • Etienne-Mastroianni B; Dept of Respiratory Medicine, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France Claude Bernard University Lyon 1, Lyon, France.
  • Vincent M; Pulmonology Dept, Saint Joseph-Saint Luc Hospital, Lyon, France.
  • Trédaniel J; Pulmonology Dept, Paris - Saint Joseph Hospital, and Sorbonne Paris Cité University, Paris, France.
  • Perrichon M; Pulmonology Dept, Bourg-en-Bresse General Hospital, Bourg en Bresse, France.
  • Foucher P; Thoracic Oncology, Dijon University Hospital, Dijon, France.
  • Coudert B; Oncology Dept, Georges François Leclerc Cancer Centre, Dijon, France.
  • Moro-Sibilot D; Pulmonology and Thoracic Oncology Dept, Grenoble University Hospital, Grenoble, France Medicine Faculty, Joseph Fourrier University, La Tronche, France.
  • Dansin E; Oncology Dept, Oscar Lambret Cancer Centre, Lille, France.
  • Labonne S; Dept of Respiratory Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France Faculty of Medicine Lyon-Sud Charles Mérieux, Lyon 1 University, Lyon, France.
  • Missy P; Intergroupe Francophone de Cancérologie Thoracique, Paris, France.
  • Morin F; Intergroupe Francophone de Cancérologie Thoracique, Paris, France.
  • Blanché H; Fondation Jean Dausset - CEPH, Paris, France.
  • Zalcman G; Pulmonology and Thoracic Oncology Dept, Caen University Hospital, and UMR INSERM 1086, Caen Basse-Normandie University, Caen, France.
Eur Respir J ; 45(5): 1403-14, 2015 May.
Article in En | MEDLINE | ID: mdl-25657019
ABSTRACT
Lung cancer in never-smokers (LCINS) (fewer than 100 cigarettes in lifetime) is considered as a distinct entity and harbours an original molecular profile. However, the epidemiological and molecular features of LCINS in Europe remain poorly understood. All consecutive newly diagnosed LCINS patients were included in this prospective observational study by 75 participating centres during a 14-month period. Each patient completed a detailed questionnaire about risk factor exposure. Biomarker and pathological analyses were also collected. We report the main descriptive overall results with a focus on sex differences. 384 patients were included 65 men and 319 women. 66% had been exposed to passive smoking (significantly higher among women). Definite exposure to main occupational carcinogens was significantly higher in men (35% versus 8% in women). A targetable molecular alteration was found in 73% of patients (without any significant sex difference) EGFR in 51%, ALK in 8%, KRAS in 6%, HER2 in 3%, BRAF in 3%, PI3KCA in less than 1%, and multiple in 2%. We present the largest and most comprehensive LCINS analysis in a European population. Physicians should track occupational exposure in men (35%), and a somatic molecular alteration in both sexes (73%).
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Lung Neoplasms Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Year: 2015 Type: Article

Full text: 1 Database: MEDLINE Main subject: Lung Neoplasms Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Year: 2015 Type: Article